BROADWAY trial

Study / Research

A large phase 3 trial for Obicetrapib in ASCVD patients, showing a 35% LDL lowering and a 21% reduction in MACE over one year.

Mentioned in 1 video

Videos Mentioning BROADWAY trial

407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more

407 ‒ Preventing cardiovascular and Alzheimer’s disease: lowering LDL early, APOE4, and more

Peter Attia MD

A large phase 3 trial for Obicetrapib in ASCVD patients, showing a 35% LDL lowering and a 21% reduction in MACE over one year.